

## Rezvilutamide: Adis Evaluation

### Key Points

- A second-generation androgen receptor antagonist being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of prostate cancer
- Received its first approval on 28 June 2022 in China
- Approved for use in patients with mHSPC with high tumour burden

### Summary

Rezvilutamide, an oral second-generation AR antagonist, is being developed by Jiangsu Hengrui Medicine Co. Ltd for the treatment of prostate cancer.

Rezvilutamide was approved in June 2022 in China for the treatment of patients aged  $\geq 18$  years with mHSPC, with a high tumour burden.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.